Morihito Okada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Morihito Okada has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Yoshihiro Miyata
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
14 shared publicationsTakahiro Mimae
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
13 shared publicationsHaruhiko Nakayama
Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan
7 shared publicationsNorifumi Tsubokawa
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
7 shared publicationsHiroyuki Ito
Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan
6 shared publicationsYasuhiro Tsutani
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
6 shared publications
Latest Publications
- Open Access
- 13 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1434249
Role of guanylate-binding protein 1 in the proliferation of invasive lung adenocarcinoma cells
Background: Guanylate-binding protein 1 (GBP1) is involved in the malignant progression of lung adenocarcinoma, particularly in the acquisition of invasive potential. However, its role in tumor proliferation and therapeutic viability in invasive lung adenocarcinomas remains unclear.Methods: This study included 99 patients with invasive lung adenocarcinoma, excluding those with non-invasive lepidic components, who had undergone complete pulmonary resection. Immunohistochemical staining was performed to examine the presence of GBP1, and its prognostic significance was assessed using uni- and multi-variable Cox regression analyses. Additionally, the expression levels of GBP1 gene and protein levels were evaluated in lung adenocarcinoma cell lines (PC-9, A549, NCI-H322, NCI-H441, NCI-H820, and ABC-1), and its proliferative role in these cell lines was analyzed using specific inhibitors targeting GBP1.Results: GBP1 expression was detected in 45 (45.5%) patients. The 5-year overall survival rates for GBP1-positive and -negative patients were 66.0% (95% confidence interval (CI): 46.3–80.0%) and 85.7% (95% CI: 72.0–93.0%), respectively (P = 0.029). The multivariable analysis demonstrated that GBP1 positivity was an independent factor for poor overall survival (hazard ratio [HR] = 2.52 [95% CI: 1.02–6.22], P = 0.045). GBP1 gene and protein were markedly expressed in NCI-H820 than in NCI-H322 and ABC-1. The inhibitor targeting GBP1 significantly suppressed the growth of NCI-H820 but not that of NCI-H322 or ABC-1.Conclusions: GBP1 is a prognostic factor that may be involved in the proliferation of invasive lung adenocarcinoma, suggesting that inhibiting GBP1 activity may be a promising therapeutic approach for lung adenocarcinoma patients expressing GBP1.
- 13 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1434249
Open AccessRole of guanylate-binding protein 1 in the proliferation of invasive lung adenocarcinoma cells
Background: Guanylate-binding protein 1 (GBP1) is involved in the malignant progression of lung adenocarcinoma, particularly in the acquisition of invasive potential. However, its role in tumor proliferation and therapeutic viability in invasive lung adenocarcinomas remains unclear.Methods: This study included 99 patients with invasive lung adenocarcinoma, excluding those with non-invasive lepidic components, who had undergone complete pulmonary resection. Immunohistochemical staining was performed to examine the presence of GBP1, and its prognostic significance was assessed using uni- and multi-variable Cox regression analyses. Additionally, the expression levels of GBP1 gene and protein levels were evaluated in lung adenocarcinoma cell lines (PC-9, A549, NCI-H322, NCI-H441, NCI-H820, and ABC-1), and its proliferative role in these cell lines was analyzed using specific inhibitors targeting GBP1.Results: GBP1 expression was detected in 45 (45.5%) patients. The 5-year overall survival rates for GBP1-positive and -negative patients were 66.0% (95% confidence interval (CI): 46.3–80.0%) and 85.7% (95% CI: 72.0–93.0%), respectively (P = 0.029). The multivariable analysis demonstrated that GBP1 positivity was an independent factor for poor overall survival (hazard ratio [HR] = 2.52 [95% CI: 1.02–6.22], P = 0.045). GBP1 gene and protein were markedly expressed in NCI-H820 than in NCI-H322 and ABC-1. The inhibitor targeting GBP1 significantly suppressed the growth of NCI-H820 but not that of NCI-H322 or ABC-1.Conclusions: GBP1 is a prognostic factor that may be involved in the proliferation of invasive lung adenocarcinoma, suggesting that inhibiting GBP1 activity may be a promising therapeutic approach for lung adenocarcinoma patients expressing GBP1.
- Open Access
- 13 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5055-5063
The Role of Emphysema on Postoperative Prognosis in Early-Stage Nonsmall Cell Lung Cancer
Background: Emphysema is generally considered a poor prognostic factor for patients with nonsmall cell lung cancer; however, whether the poor prognosis is due to highly malignant tumors or emphysema itself remains unclear. This study was designed to determine the prognostic value of emphysema in patients with early-stage nonsmall cell lung cancer. Methods: A total of 721 patients with clinical stage IA nonsmall cell lung cancer who underwent complete resection between April 2007 and December 2018 were retrospectively analyzed regarding clinicopathological findings and prognosis related to emphysema. Results: The emphysematous and normal lung groups comprised 197 and 524 patients, respectively. Compared with the normal lung group, lymphatic invasion (23.9% vs. 14.1%, P = 0.003), vascular invasion (37.6% vs. 17.2%, P < 0.001), and pleural invasion (18.8% vs. 10.9%, P = 0.006) were observed more frequently in the emphysema group. Additionally, the 5-year overall survival rate was lower (77.1% vs. 91.4%, P < 0.001), and the cumulative incidence of other causes of death was higher in the emphysema group (14.0% vs. 3.50%, P < 0.001). Multivariable Cox regression analysis of overall survival revealed that emphysema (vs. normal lung, hazard ratio 2.02, P = 0.0052), age > 70 years (vs. < 70 years, hazard ratio 4.03, P < 0.001), and SUVmax > 1.8 (vs. ≤ 1.8, hazard ratio 2.20, P = 0.0043) were independent prognostic factors. Conclusions: Early-stage nonsmall cell lung cancer with emphysema has a tendency for the development of highly malignant tumors. Additionally, emphysema itself may have an impact on poor prognosis.
- 13 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5055-5063
Open AccessThe Role of Emphysema on Postoperative Prognosis in Early-Stage Nonsmall Cell Lung Cancer
Background: Emphysema is generally considered a poor prognostic factor for patients with nonsmall cell lung cancer; however, whether the poor prognosis is due to highly malignant tumors or emphysema itself remains unclear. This study was designed to determine the prognostic value of emphysema in patients with early-stage nonsmall cell lung cancer. Methods: A total of 721 patients with clinical stage IA nonsmall cell lung cancer who underwent complete resection between April 2007 and December 2018 were retrospectively analyzed regarding clinicopathological findings and prognosis related to emphysema. Results: The emphysematous and normal lung groups comprised 197 and 524 patients, respectively. Compared with the normal lung group, lymphatic invasion (23.9% vs. 14.1%, P = 0.003), vascular invasion (37.6% vs. 17.2%, P < 0.001), and pleural invasion (18.8% vs. 10.9%, P = 0.006) were observed more frequently in the emphysema group. Additionally, the 5-year overall survival rate was lower (77.1% vs. 91.4%, P < 0.001), and the cumulative incidence of other causes of death was higher in the emphysema group (14.0% vs. 3.50%, P < 0.001). Multivariable Cox regression analysis of overall survival revealed that emphysema (vs. normal lung, hazard ratio 2.02, P = 0.0052), age > 70 years (vs. < 70 years, hazard ratio 4.03, P < 0.001), and SUVmax > 1.8 (vs. ≤ 1.8, hazard ratio 2.20, P = 0.0043) were independent prognostic factors. Conclusions: Early-stage nonsmall cell lung cancer with emphysema has a tendency for the development of highly malignant tumors. Additionally, emphysema itself may have an impact on poor prognosis.
- Open Access
- 8 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4323-4324
ASO Author Reflections: How Does Emphysema Contribute to Poor Prognosis After Lung Cancer Surgery?
- 8 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4323-4324
Open AccessASO Author Reflections: How Does Emphysema Contribute to Poor Prognosis After Lung Cancer Surgery?
- 19 March 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (1) , 192-198
Omitting Lymph Node Dissection for Small Ground-Glass Opacity–Dominant Tumors
- 19 March 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (1) , 192-198
Omitting Lymph Node Dissection for Small Ground-Glass Opacity–Dominant Tumors
- 23 March 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (4) , 859
Segmentectomy and Wedge Resection Should Be Distinguished as Sublobar Resections for Lung Cancer
- 23 March 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (4) , 859
Segmentectomy and Wedge Resection Should Be Distinguished as Sublobar Resections for Lung Cancer
- Open Access
- 20 February 2022
- Published by Elsevier in JTCVS Techniques
- Vol. 12, 210-211
Commentary: Segmentectomy as a standard surgery, a new era in small sized, peripheral, non–small cell lung cancer
- 20 February 2022
- Published by Elsevier in JTCVS Techniques
- Vol. 12, 210-211
Open AccessCommentary: Segmentectomy as a standard surgery, a new era in small sized, peripheral, non–small cell lung cancer
- 30 July 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (10) , 1561-1569
Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy
We aimed to determine the influences of surgical procedures on the postoperative death of octogenarians with clinical Stage IA non-small cell lung cancer excluding cT1mi. We compared overall survival and the cumulative incidence of death due to all and other causes among 1 130 279, and 191 consecutive patients aged ≤79 and ≥80 years after lobectomy, segmentectomy and wedge resection at three institutions. Death due to other causes was defined as death due to any cause except non-small cell lung cancer. The median followup was 53 months. The 5-year overall survival rates for patients aged ≥ 80 and ≤ 79 years after lobectomy, segmentectomy and wedge resection were respectively, 78.0% (95% confidence interval, 63.8%–87.2%) versus 91.2% (95% confidence interval, 89.0%–92.9%), 68.1% (95% confidence interval, 45.2%–83.1%) versus 90.0% (95% confidence interval, 84.6%–93.5%), and 62.7% (95% confidence interval, 44.0–76.7%) versus 84.4% (95% confidence interval, 76.3%–89.9%) (P < 0.01 for all). The cumulative incidence of death due to other causes after wedge resection was similar between patients aged ≥ 80 and ≤ 79 years (P = 0.45), but significantly higher in those aged ≥ 80, than ≤ 79 years after lobectomy or segmentectomy (P = 0.00015 and 0.00091, respectively). The influence of wedge resection on death due to other causes was lower than that of lobectomy or segmentectomy in patients with non-small cell lung cancer aged ≥ 80 years. Wedge resection might be a useful option for octogenarians even if they can tolerate lobectomy/segmentectomy to avoid postoperative death due to causes other than non-small cell lung cancer.
- 30 July 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (10) , 1561-1569
Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy
We aimed to determine the influences of surgical procedures on the postoperative death of octogenarians with clinical Stage IA non-small cell lung cancer excluding cT1mi. We compared overall survival and the cumulative incidence of death due to all and other causes among 1 130 279, and 191 consecutive patients aged ≤79 and ≥80 years after lobectomy, segmentectomy and wedge resection at three institutions. Death due to other causes was defined as death due to any cause except non-small cell lung cancer. The median followup was 53 months. The 5-year overall survival rates for patients aged ≥ 80 and ≤ 79 years after lobectomy, segmentectomy and wedge resection were respectively, 78.0% (95% confidence interval, 63.8%–87.2%) versus 91.2% (95% confidence interval, 89.0%–92.9%), 68.1% (95% confidence interval, 45.2%–83.1%) versus 90.0% (95% confidence interval, 84.6%–93.5%), and 62.7% (95% confidence interval, 44.0–76.7%) versus 84.4% (95% confidence interval, 76.3%–89.9%) (P < 0.01 for all). The cumulative incidence of death due to other causes after wedge resection was similar between patients aged ≥ 80 and ≤ 79 years (P = 0.45), but significantly higher in those aged ≥ 80, than ≤ 79 years after lobectomy or segmentectomy (P = 0.00015 and 0.00091, respectively). The influence of wedge resection on death due to other causes was lower than that of lobectomy or segmentectomy in patients with non-small cell lung cancer aged ≥ 80 years. Wedge resection might be a useful option for octogenarians even if they can tolerate lobectomy/segmentectomy to avoid postoperative death due to causes other than non-small cell lung cancer.
- 1 May 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (5) , 1530-1536
Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors
- 1 May 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (5) , 1530-1536
Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors
- 27 August 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (11) , 1015-1021
Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma
Although the recent reclassification of histological subtypes of lung adenocarcinoma reflects disease prognosis better, the prognosis of papillary and acinar-predominant adenocarcinoma, which are highly prevalent, is heterogeneity. The present study aimed to identify the prognostic indicators for papillary and acinar-predominant adenocarcinoma. This retrospective study included 315 consecutive patients with completely resected pathological N0 lung adenocarcinoma tumors ≤3 cm from two institutions. Tumors were classified according to histologically predominant subtypes as low-grade (adenocarcinoma in situ, minimally invasive adenocarcinoma or lepidic predominant), intermediate-grade (papillary or acinar predominant) or high-grade (solid or micropapillary predominant). Prognostic factors in intermediate-grade group were assessed among clinicopathological factors of age, gender, surgical procedure, tumor size, pleural, lymphatic and vascular invasion using Cox proportion hazards analyses. There were 174 patients in the low-grade group, 109 in the intermediate-grade group and 32 in the high-grade group. The 3-year recurrence-free survival rates were 98.1%, 86.3% and 74.8% for these groups, respectively (P < 0.001). In the intermediate-grade group, the presence of vascular invasion was an independent prognostic factor on multivariate Cox regression analysis of recurrence-free survival (hazard ratio, 3.48; 95% confidence interval, 1.26–9.57, P = 0.01). Classification of intermediate-grade group based on vascular invasion revealed a clear division into favorable and unfavorable prognostic subgroups. Consideration of the vascular invasion status in addition to the predominant subtype could provide a more accurate assessment of malignant aggressiveness and prognosis of patients with early-stage lung adenocarcinoma.
- 27 August 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (11) , 1015-1021
Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma
Although the recent reclassification of histological subtypes of lung adenocarcinoma reflects disease prognosis better, the prognosis of papillary and acinar-predominant adenocarcinoma, which are highly prevalent, is heterogeneity. The present study aimed to identify the prognostic indicators for papillary and acinar-predominant adenocarcinoma. This retrospective study included 315 consecutive patients with completely resected pathological N0 lung adenocarcinoma tumors ≤3 cm from two institutions. Tumors were classified according to histologically predominant subtypes as low-grade (adenocarcinoma in situ, minimally invasive adenocarcinoma or lepidic predominant), intermediate-grade (papillary or acinar predominant) or high-grade (solid or micropapillary predominant). Prognostic factors in intermediate-grade group were assessed among clinicopathological factors of age, gender, surgical procedure, tumor size, pleural, lymphatic and vascular invasion using Cox proportion hazards analyses. There were 174 patients in the low-grade group, 109 in the intermediate-grade group and 32 in the high-grade group. The 3-year recurrence-free survival rates were 98.1%, 86.3% and 74.8% for these groups, respectively (P < 0.001). In the intermediate-grade group, the presence of vascular invasion was an independent prognostic factor on multivariate Cox regression analysis of recurrence-free survival (hazard ratio, 3.48; 95% confidence interval, 1.26–9.57, P = 0.01). Classification of intermediate-grade group based on vascular invasion revealed a clear division into favorable and unfavorable prognostic subgroups. Consideration of the vascular invasion status in addition to the predominant subtype could provide a more accurate assessment of malignant aggressiveness and prognosis of patients with early-stage lung adenocarcinoma.